CVS
CVS Health Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-4/100
Last price
86.60
▼ 0.41 (0.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
87.37
Prev close
87.01
Day high
87.08
Day low
85.53
Volume
11.04M
Market cap
$110.54B
P/E (TTM)
22.93
52W range
69.51 – 110.68
Day trading desk
Gap from prior close
+0.41%
Prior close 87.01
VWAP
86.28
+0.37% from price
Relative volume
2.34×
Unusually busy
Session range
2.16%
85.53 – 87.37
Position in range
58%
Mid range
ATR (14D)
1.97
2.28% of price
Prior day high
87.51
PDH
Prior day low
86.33
PDL
Bid / ask spread
—
Quote not published
Session volume
18.49M
Avg 7.91M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.77%
-2.7%
1M
-10.66%
-11.8%
3M
-17.27%
-21.8%
6M
+10.50%
-7.7%
YTD
+8.91%
-5.3%
1Y
+11.54%
-4.9%
3Y
+23.79%
-58.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-3.43M
Net selling
Buy transactions
6
9.51K shares
Sell transactions
2
3.44M shares
Net transactions
+8
Buys less sells
Sell : buy shares
362.0 : 1
Heavily one-sided
Insider-held shares
805.75K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 21, 26 | ROBBINS LARRY Director |
SELL | 3.37M | $317.47M | Indirect |
| May 14, 26 | BROWN C DAVID II Director |
STOCK | 1.54K | $150.00K | Direct |
| May 14, 26 | KIRBY JOHN SCOTT Director |
STOCK | 1.45K | $140.58K | Direct |
| May 14, 26 | SANSONE GUY P Director |
STOCK | 1.45K | $140.58K | Direct |
| May 14, 26 | AGUIRRE FERNANDO Director |
STOCK | 1.56K | $151.84K | Direct |
| May 14, 26 | BALSER JEFFREY R M.D., PH.D. Director |
STOCK | 2.06K | $199.94K | Direct |
| May 14, 26 | NORWALK LESLIE V Director |
STOCK | 1.45K | $140.58K | Direct |
| May 8, 26 | MANDADI TILAK Officer |
SELL | 69.55K | $6.23M | Direct |
| Mar 31, 26 | JOYNER JOHN DAVID Chief Executive Officer |
STOCK | 86.33K | $6.20M | Direct |
| Mar 31, 26 | NELSON STEVEN H Officer |
STOCK | 22.28K | $1.60M | Direct |
| Mar 31, 26 | MANDADI TILAK Officer |
STOCK | 22.28K | $1.60M | Direct |
| Mar 31, 26 | SHAH PREM S Officer |
STOCK | 25.06K | $1.80M | Direct |
| Mar 31, 26 | CAPOZZI HEIDI B Officer |
STOCK | 10.03K | $720.00K | Direct |
| Mar 31, 26 | COMPTON-PHILLIPS AMY Officer |
STOCK | 5.57K | $399.97K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROWN C DAVID II |
Director | 129.32K | Stock Award(Grant) |
CAPOZZI HEIDI B |
Officer | 97.47K | Stock Award(Grant) |
COMPTON-PHILLIPS AMY |
Officer | 58.66K | Stock Award(Grant) |
COWHEY THOMAS F. |
Chief Financial Officer | 91.30K | Stock Award(Grant) |
FARAH ROGER N |
Director | 54.25K | Stock Award(Grant) |
JOYNER JOHN DAVID |
Chief Executive Officer | 231.21K | Stock Award(Grant) |
KHICHI SAMRAT S |
General Counsel | 71.56K | Stock Award(Grant) |
MILLON JEAN PIERRE |
Director | 112.22K | Stock Award(Grant) |
ROBBINS LARRY |
Director | — | Sale |
SHAH PREM S |
Officer | 127.21K | Stock Award(Grant) |
Fundamentals
Market cap$110.54B
Enterprise value$173.09B
Revenue (TTM)$412.64B
Gross profit$56.31B
EBITDA$16.68B
Net income$4.89B
EPS (TTM)$3.77
Free cash flow$8.08B
Total cash$13.96B
Total debt$76.31B
Book value / share$62.37
Shares outstanding1.28B
Float1.28B
Short % of float1.27%
Dividend yield3.06%
Beta (5Y)0.60
Valuation & profitability ratios
Trailing P/E22.93
Forward P/E10.13
PEG ratio0.20
Price / sales—
Price / book1.39
EV / revenue0.42
EV / EBITDA10.38
Gross margin13.65%
Operating margin3.86%
Profit margin1.18%
Return on equity6.21%
Return on assets2.97%
Debt / equity95.50
Current ratio0.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $402.07B | $372.81B | $357.78B | $322.47B | +7.8% |
| Operating revenue | $402.07B | $372.81B | $357.78B | $322.47B | +7.8% |
| Cost of revenue | $346.70B | $321.41B | $303.35B | $267.96B | +7.9% |
| Gross profit | $55.36B | $51.40B | $54.43B | $54.50B | +7.7% |
| Total operating expense | $44.98B | $41.71B | $39.83B | $38.21B | +7.8% |
| Operating income | $10.38B | $9.70B | $14.60B | $16.29B | +7.1% |
| Net interest income | -$3.12B | -$2.96B | -$2.66B | -$2.29B | -5.4% |
| Pre-tax income | $2.14B | $6.15B | $11.17B | $5.84B | -65.3% |
| Tax provision | $408.00M | $1.56B | $2.81B | $1.51B | -73.9% |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | -61.7% |
| Net income to common | $1.77B | $4.61B | $8.34B | $4.31B | -61.7% |
| Basic EPS | 1.40 | 3.67 | 6.49 | 3.29 | -61.9% |
| Diluted EPS | 1.39 | 3.66 | 6.47 | 3.26 | -62.0% |
| EBIT | $5.25B | $9.11B | $13.83B | $8.12B | -42.3% |
| EBITDA | $9.86B | $13.70B | $18.20B | $12.35B | -28.0% |
| Basic shares | 1.27B | 1.26B | 1.28B | 1.31B | +0.6% |
| Diluted shares | 1.27B | 1.26B | 1.29B | 1.32B | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.45B | $8.59B | $8.20B | $12.95B | -1.5% |
| Cash & short-term investments | $10.60B | $10.99B | $11.46B | $15.72B | -3.6% |
| Accounts receivable | $16.32B | $14.61B | $15.62B | $11.66B | +11.7% |
| Inventory | $19.25B | $18.11B | $18.02B | $19.09B | +6.3% |
| Total current assets | $74.71B | $68.64B | $67.86B | $65.63B | +8.8% |
| Property, plant & equipment | $28.06B | $28.94B | $30.43B | $30.75B | -3.0% |
| Goodwill & intangibles | $110.99B | $118.59B | $120.51B | $102.95B | -6.4% |
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | +0.1% |
| Total current liabilities | $88.69B | $84.61B | $79.19B | $69.42B | +4.8% |
| Current debt | $4.07B | $5.74B | $2.97B | $1.78B | -29.2% |
| Long-term debt | $60.50B | $60.53B | $58.64B | $50.48B | -0.0% |
| Total debt | $79.95B | $82.92B | $79.39B | $70.73B | -3.6% |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | +0.4% |
| Retained earnings | $61.20B | $62.84B | $61.60B | $56.40B | -2.6% |
| Shareholder equity | $75.21B | $75.56B | $76.46B | $71.47B | -0.5% |
| Working capital | -$13.98B | -$15.96B | -$11.33B | -$3.79B | +12.4% |
| Net tangible assets | -$35.77B | -$43.03B | -$44.05B | -$31.48B | +16.9% |
| Shares issued | 1.79B | 1.78B | 1.77B | 1.76B | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.73B | $4.59B | $8.37B | $4.33B | -62.3% |
| Depreciation & amortisation | $4.61B | $4.60B | $4.37B | $4.22B | +0.2% |
| Stock-based compensation | $535.00M | $540.00M | $588.00M | $447.00M | -0.9% |
| Change in working capital | -$1.47B | $109.00M | $15.00M | $6.82B | -1,452.3% |
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | +16.8% |
| Capital expenditure | -$2.83B | -$2.78B | -$3.03B | -$2.73B | -1.8% |
| Investing cash flow | -$5.87B | -$7.61B | -$20.89B | -$5.05B | +22.9% |
| Share buybacks | $0 | -$3.02B | -$2.01B | -$3.50B | +100.0% |
| Dividends paid | -$3.40B | -$3.37B | -$3.13B | -$2.91B | -0.7% |
| Financing cash flow | -$4.94B | -$1.14B | $2.68B | -$10.52B | -335.2% |
| Free cash flow | $7.81B | $6.33B | $10.39B | $13.45B | +23.4% |
| End cash position | $8.71B | $8.88B | $8.53B | $13.30B | -1.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $106.10B | $100.43B | $105.69B | $102.87B | $98.92B | +5.6% |
| Operating revenue | $106.10B | $100.43B | $105.69B | $102.87B | $98.92B | +5.6% |
| Cost of revenue | $90.35B | $84.80B | $92.13B | $89.06B | $85.32B | +6.5% |
| Gross profit | $15.75B | $15.62B | $13.57B | $13.81B | $13.59B | +0.8% |
| Total operating expense | $11.05B | $10.94B | $11.46B | $11.29B | $11.21B | +0.9% |
| Operating income | $4.70B | $4.68B | $2.11B | $2.52B | $2.38B | +0.5% |
| Net interest income | -$757.00M | -$774.00M | -$787.00M | -$784.00M | -$763.00M | +2.2% |
| Pre-tax income | $3.98B | $3.94B | $1.35B | -$3.48B | $1.65B | +1.0% |
| Tax provision | $982.00M | $981.00M | -$1.57B | $508.00M | $634.00M | +0.1% |
| Net income | $2.98B | $2.94B | $2.94B | -$3.98B | $1.02B | +1.2% |
| Net income to common | $2.98B | $2.94B | $2.94B | -$3.98B | $1.02B | +1.2% |
| Basic EPS | 2.33 | 2.31 | 2.32 | -3.13 | 0.81 | +0.9% |
| Diluted EPS | 2.31 | 2.30 | 2.30 | -3.13 | 0.80 | +0.4% |
| EBIT | $4.73B | $4.71B | $2.14B | -$2.70B | $2.41B | +0.5% |
| EBITDA | $5.86B | $5.83B | $3.29B | -$1.56B | $3.58B | +0.6% |
| Basic shares | 1.28B | 1.27B | 1.27B | 1.27B | 1.27B | +0.5% |
| Diluted shares | 1.29B | 1.28B | 1.28B | 1.27B | 1.27B | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.33B | $9.54B | $8.45B | $9.10B | $11.79B | +18.7% |
| Cash & short-term investments | $13.96B | $11.80B | $10.60B | $11.23B | $14.17B | +18.3% |
| Accounts receivable | $19.38B | $20.14B | $16.32B | $16.10B | $16.35B | -3.8% |
| Inventory | $17.62B | $17.77B | $19.25B | $18.96B | $17.45B | -0.8% |
| Total current assets | $75.35B | $74.82B | $74.71B | $77.11B | $75.65B | +0.7% |
| Property, plant & equipment | $27.62B | $27.78B | $28.06B | $28.11B | $28.34B | -0.6% |
| Goodwill & intangibles | $110.12B | $110.55B | $110.99B | $111.46B | $117.43B | -0.4% |
| Total assets | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | +0.3% |
| Total current liabilities | $87.04B | $86.41B | $88.69B | $92.69B | $94.16B | +0.7% |
| Current debt | $1.96B | $2.58B | $4.07B | $5.33B | $9.20B | -24.1% |
| Long-term debt | $59.45B | $60.53B | $60.50B | $60.51B | $57.29B | -1.8% |
| Total debt | $76.31B | $78.34B | $79.95B | $81.75B | $82.72B | -2.6% |
| Total liabilities | $173.87B | $175.34B | $178.16B | $182.22B | $180.79B | -0.8% |
| Retained earnings | $65.40B | $63.28B | $61.20B | $59.11B | $63.94B | +3.3% |
| Shareholder equity | $79.70B | $77.46B | $75.21B | $72.93B | $77.38B | +2.9% |
| Working capital | -$11.70B | -$11.59B | -$13.98B | -$15.59B | -$18.51B | -0.9% |
| Net tangible assets | -$30.42B | -$33.09B | -$35.77B | -$38.53B | -$40.05B | +8.1% |
| Shares issued | 1.28B | 1.79B | 1.79B | 1.79B | 1.78B | -28.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $3.00B | $2.96B | $2.92B | -$3.99B | $1.01B | — | +1.3% |
| Depreciation & amortisation | $1.13B | $1.11B | $1.15B | $1.13B | $1.17B | — | +1.0% |
| Stock-based compensation | $176.00M | $266.00M | $135.00M | $138.00M | $136.00M | — | -33.8% |
| Change in working capital | $2.20B | $2.00M | -$1.02B | -$1.57B | -$309.00M | — | +109,800.0% |
| Operating cash flow | $6.34B | $4.25B | $3.39B | $796.00M | $1.90B | — | +49.3% |
| Capital expenditure | -$691.00M | -$849.00M | -$784.00M | -$698.00M | -$607.00M | — | +18.6% |
| Investing cash flow | -$1.88B | -$874.00M | -$2.00B | -$2.09B | -$1.02B | — | -115.6% |
| Share buybacks | — | — | $0 | $0 | $0 | $0 | — |
| Dividends paid | -$878.00M | -$847.00M | -$845.00M | -$846.00M | -$866.00M | — | -3.7% |
| Financing cash flow | -$2.69B | -$2.32B | -$2.03B | -$1.38B | $806.00M | — | -16.2% |
| Free cash flow | $5.65B | $3.40B | $2.61B | $98.00M | $1.29B | — | +66.3% |
| End cash position | $11.54B | $9.77B | $8.71B | $9.35B | $12.03B | — | +18.1% |
Options analytics
Put / call volume
0.50
Call-heavy session
Put / call open interest
0.61
Positioning, not flow
Max pain
87.00
+0.7% from spot
ATM implied vol
49.6%
Nearest strike to spot
Skew (10% OTM)
-13.3%
Calls bid over puts
Call volume
5.22K
Contracts, this expiry
Put volume
2.59K
Contracts, this expiry
Heaviest call OI
88.00
2.12K contracts
Heaviest put OI
87.00
1.45K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.85 | 2.58 | +39.4% |
| Mar 2026 | 2.21 | 2.57 | +16.5% |
| Dec 2025 | 1.00 | 1.09 | +9.4% |
| Sep 2025 | 1.36 | 1.60 | +17.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.64 | 23 | $104.81B | +1.9% |
| Next quarter | 1.26 | 23 | $106.96B | +1.2% |
| Current year | 8.04 | 25 | $418.05B | +4.0% |
| Next year | 8.53 | 26 | $430.06B | +2.9% |
Analyst targets & ownership
Mean target$115.76
High target$145.00
Low target$103.00
Implied upside33.67%
Analyst count25
ConsensusSTRONG BUY
Strong buy / Buy7 / 18
Hold2
Sell / Strong sell0 / 0
Held by insiders0.06%
Held by institutions90.83%
Institutions holding2.66K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
86.58
+0.03% from price
SMA 20
89.33
-3.25% from price
SMA 50
94.08
-8.13% from price
SMA 100
97.17
-10.88% from price
SMA 200
87.77
-1.53% from price
EMA 12
87.49
-1.01% from price
EMA 26
89.95
-3.72% from price
EMA 50
92.61
-6.49% from price
RSI (14)
37.6
Neutral
MACD (12,26,9)
-2.46
Hist 0.04
ATR (14)
1.97
2.28% of price
Realised vol 30D
24.8%
Annualised
Bollinger upper
96.69
20, 2σ
Bollinger lower
81.98
20, 2σ
50 / 200 cross
Golden
94.08 vs 87.77
Trend bias
Below 200
-1.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.17
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
24.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-23.1%
Peak to trough
Max drawdown 5Y
-60.5%
Peak to trough
ATR 14
1.97
2.28% of price
Beta (reported)
0.60
5Y monthly, from filing
Short interest
Shares short
16.12M
Prior 16.82M
Change vs prior
-4.2%
Shorts covering
% of float
1.27%
Normal
% of shares out
1.26%
Against total outstanding
Days to cover
2.8
Liquid
Float
1.28B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 19, 26 | Argus Research | MAINTAINED | Buy | Buy |
| Aug 12, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 25, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 9, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jun 23, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$2.66 / yr
Forward yield3.06%
5-year avg yield3.01%
Payout ratio70.00%
Ex-dividend dateOct 22, 2026
Next pay dateNov 2, 2026
Last split2:1
Split dateJun 7, 2005
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-17
Corporate Changes & Voting Matters
8-K · 2026-08-05
Annual report of employee stock purchase
11-K · 2026-06-23
Offering Registrations
S-8 · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-18
Periodic Financial Reports
10-Q · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-03
Corporate Changes & Voting Matters
8-K · 2026-03-19
Headlines
HPV Vaccination and Cervical Cancer Prevention: One of Public Health's Greatest Opportunities
ACCESS Newswire · 12h ago
CVS Health Faces 340B Headwinds, Larger Earnings Risks in 2027, BofA Says
MT Newswires · 12h ago
CVS' Health Care Benefits Arm Shows Better Core Trends: What's Ahead?
Zacks · 15h ago
BofA Securities Adjusts CVS Health Price Target to $110 From $120, Maintains Buy Rating
MT Newswires · 16h ago
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
Zacks · 2d ago
Amazon pulls a best-selling pain reliever again, and customers need to check their medicine cabinets
TheStreet · 2d ago
Amazon pulls a best-selling pain reliever again, and customers need to check their medicine cabinets
TheStreet · 2d ago
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.